Evidence map›Paper›PMID 31996422›Full record

Trial reportmSphere2020

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection.

Zanele Ditse, Nonhlanhla N Mkhize, Michael Yin, Michael Keefer, David C Montefiori, Georgia D Tomaras, Gavin Churchyard, Kenneth H Mayer, Shelly Karuna, Cecilia Morgan and 8 more

Open access · goldAbstract readClinical Trial, Phase IClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 2 countries.

Zanele DitseNational Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.
Nonhlanhla N MkhizeNational Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.
Michael YinDepartment of Medicine, Columbia University, New York, New York, USA.
Michael KeeferDepartment of Medicine, University of Rochester, Rochester, New York, USA.
David C MontefioriDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Gavin ChurchyardAurum Institute, Parktown, South Africa.
Kenneth H MayerFenway Health, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Shelly KarunaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Cecilia MorganVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Linda-Gail BekkerInstitute for Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Koleka MlisanaUniversity of Kwa-Zulu Natal, Durban, South Africa.
Glenda GrayVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Zoe MoodieVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Peter GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Penny L MooreNational Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.ORCID https://orcid.org/0000-0001-8719-4028
Carolyn WilliamsonInstitute for Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Lynn MorrisNational Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa lynnm@nicd.ac.za.ORCID https://orcid.org/0000-0003-3961-7828
National Health Laboratory Service · ZAFred Hutch Cancer Center · USDuke Medical Center · USBeth Israel Deaconess Medical Center · USColumbia University · USSouth African Medical Research Council · ZAUniversity of Cape Town · ZAUniversity of Rochester · USUniversity of the Witwatersrand · ZAUniversity of Washington · US

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI069470
6 · The paper itself

Abstract

Analysis of breakthrough HIV-1 infections could elucidate whether prior vaccination primes relevant immune responses. Here, we measured HIV-specific antibody responses in 14 South African volunteers who acquired HIV infection after participating in phase 1/2 trials of envelope-containing immunogens. Serum samples were collected annually following HIV-1 infection from participants in trials HVTN 073 (subtype C, DNA/MVA, phase 1 trial,

Indexed as

AdultAIDS VaccinesAntibodies, NeutralizingAntibody Formationenv Gene Products, Human Immunodeficiency VirusEnzyme-Linked Immunosorbent AssayFemaleHIV-1HIV AntibodiesHIV Envelope Protein gp41HIV InfectionsHumansMaleMiddle AgedNeutralization TestsViral LoadAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesHIV Envelope Protein gp41binding antibody epitopesbroadly neutralizing antibodiesDNA/MVA vaccinesHIV-1 envelopeHIV breakthrough infectionsHIV-specific binding antibodiesHIV vaccinesrAd5

Identifiers

PMID31996422
PMCPMC6992371
OpenAlexW3003676113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.